A Randomized, Comparator-controlled, Cross-over Intervention Study to Assess Renal Hemodynamics of Mono- and Combination Therapy With SGLT-2 Inhibitor Empagliflozin and RAS-inhibitor Losartan in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 27 Dec 2022
At a glance
- Drugs Empagliflozin (Primary) ; Losartan (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms RECOLAR
Most Recent Events
- 26 Dec 2022 Results of secondary analysis assessing effects of empagliflozin, losartan and their combination in people with type 2 diabetes published in the Diabetes, Obesity and Metabolism
- 04 Oct 2021 Status changed from recruiting to completed.
- 23 Nov 2020 Status changed from not yet recruiting to recruiting.